Literature DB >> 24616204

The European Medicines Agency's use of prioritised independent research for best evidence in regulatory action on diclofenac.

Peter Arlett1, Sinan B Sarac, Andrew Thomson, Claire Davies, Tania Teixeira, Kevin V Blake, Doris Stenver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24616204     DOI： 10.1002/pds.3594

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN： 1053-8569            Impact factor:   2.890


× No keyword cloud information.
  3 in total

1.  Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).

Authors:  Xavier Kurz; Susana Perez-Gutthann
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-01-11       Impact factor: 2.890

2.  Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs.

Authors:  Giampiero Mazzaglia; Sabine M J Straus; Peter Arlett; Daniela da Silva; Heidi Janssen; June Raine; Enrica Alteri
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.606

3.  Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?

Authors:  Hans-Georg Eichler; Brigitte Bloechl-Daum; Karl Broich; Paul Alexander Kyrle; Jillian Oderkirk; Guido Rasi; Rui Santos Ivo; Ad Schuurman; Thomas Senderovitz; Luke Slawomirski; Martin Wenzl; Valerie Paris
Journal:  Clin Pharmacol Ther       Date:  2018-10-14       Impact factor: 6.875
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.